FDA Approves XFG-Adapted COVID-19 Vaccine, mRNA for the 2026-2027 Season

The FDA has approved the supplemental Biologics License Application for Pfizer and BioNTech's 2026-2027 formula of COVID-19 vaccine, mRNA (Comirnaty XFG), clearing the updated shot for adults aged 65 and older and for individuals aged 5 through 64 with at least 1 underlying condition that increases their risk for severe COVID-19 outcomes. The approval marks the companies' latest strain update to the mRNA vaccine platform and follows a now-familiar seasonal cadence of realigning vaccine composition with circulating SARS-CoV-2 lineages. Shipping began immediately following authorization, with doses expected in pharmacies, hospitals, and clinics within days.¹

What Is the COVID-19 Vaccine, mRNA (Comirnaty XFG)?

Comirnaty XFG is a nucleoside-modified mRNA vaccine built on BioNTech's proprietary mRNA platform. It works by delivering lipid nanoparticle-encapsulated mRNA that instructs cells to transiently produce the SARS-CoV-2 spike glycoprotein, prompting an adaptive immune response without exposure to live virus. This iteration swaps the prior LP.8.1 spike sequence for one derived from the JN. 1-lineage XFG subvariant, the strain the FDA identified as the preferred vaccine target for the coming respiratory season.^1,2

Evidence Supporting the Approval

The FDA based this approval on the cumulative body of clinical, nonclinical, and real-world evidence Pfizer and BioNTech have generated across prior Comirnaty formulas, combined with manufacturing and quality data specific to the XFG update. Nonclinical immunogenicity data showed that the XFG-adapted vaccine elicited robust immune responses against XFG and several other currently circulating lineages, including XFG.1.1, NB.1.8.1, and PQ.17.¹

“The selection of the XFG variant is based on guidance from the FDA as the preferred composition of COVID-19 vaccines for use in the US beginning in fall 2026. Closely matching the updated vaccines with currently circulating SARS-CoV-2 variants is a critical public health strategy to help protect populations from severe COVID-19 outcomes, including hospitalizations and death,” a Pfizer spokesperson said in an interview with Pharmacy Times.

That evidence was built on the FDA's Vaccines and Related Biological Products Advisory Committee's May 2026 review of viral surveillance, antigenic characterization, and human immunogenicity data, which concluded that a monovalent JN. The 1-lineage XFG vaccine represented the best match to anticipated fall 2026 circulation. More than 5 billion Comirnaty doses have now been distributed globally, a real-world safety base the agency also weighed in on reaching its decision.^1,2

“Global regulatory authorities have determined that variant adaptations to licensed COVID-19 vaccines should require only non-clinical and manufacturing data at the time of approval. This is the same process by which the LP.8.1-adapted monovalent vaccine and other previously adapted vaccines were authorized or approved. Similar to previous variant changes, Pfizer and BioNTech plan to conduct a confirmatory clinical study. The updated COVID-19 vaccine by Pfizer and BioNTech differs from our earlier COVID-19 vaccines only in that it contains mRNA encoding for the spike protein of a different SARS-CoV-2 variant, XFG,” the spokesperson said.

Clinical Implications for Pharmacists

For pharmacists, this approval extends an established annual workflow: reformulated antigen, same platform, same administration technique, and same counseling framework. Current CDC and Advisory Committee on Immunization Practices guidance frames COVID-19 vaccination around individual decision-making for individuals 6 months and older, with the strongest risk-benefit favoring adults 65 and older and anyone with an underlying condition that elevates risk for severe disease. Pharmacists administering the updated shot should reinforce that protection from prior vaccination or infection wanes over time and that this season's formula is designed to more closely match currently circulating variants than the 2025-2026 LP.8.1-based shot it replaces.^3,4

As with prior seasonal transitions, community pharmacies should expect a short window of mixed inventory as remaining prior-formula doses are phased out in favor of the XFG-adapted product, making inventory checks and patient-specific eligibility screening (age, underlying conditions) especially important at the point of care.^3,4

Contraindications, Warnings, and Precautions

Comirnaty XFG carries the same safety profile and labeling considerations as earlier Comirnaty formulas. It is contraindicated in individuals with a history of severe allergic reaction to a previous dose of any Pfizer-BioNTech COVID-19 vaccine or to any vaccine component.¹

Myocarditis and pericarditis have been reported following mRNA COVID-19 vaccination, occurring most frequently in males 12 through 24 years of age, typically within a week of vaccination; patients should be counseled to seek care for chest pain, shortness of breath, or palpitations. Additional reported effects include injection-site reactions, fatigue, headache, myalgia, chills, and fever, along with febrile seizures in children ages 5 through 11 years. Individuals with weakened immune systems may mount a reduced immune response, and vaccination provider sites should be prepared to monitor for fainting and rare severe allergic reactions.¹

Looking Ahead

With Moderna's XFG-adapted Spikevax and mNexspike formulas also cleared this season, pharmacists will soon be counseling patients across multiple updated mRNA options ahead of fall 2026. As doses reach pharmacy shelves, continued real-world monitoring will help determine how well the XFG-targeted formula performs against the season's dominant circulating lineages.

REFERENCES

1. Pfizer and BioNTech receive U.S. FDA approval for XFG-adapted COVID-19 vaccine. News release. Pfizer Inc. August 27, 2026. Accessed August 27, 2026. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-approval-xfg-adapted

2. COVID-19 vaccines (2026-2027 formula) for use in the United States beginning in fall 2026. FDA. Updated May 29, 2026. Accessed August 27, 2026. https://www.fda.gov/vaccines-blood-biologics/industry-biologics/covid-19-vaccines-2026-2027-formula-use-united-states-beginning-fall-2026

3. ACIP recommends COVID-19 immunization based on individual decision-making. News release. HHS.gov; September 19, 2025. Accessed August 27, 2026. https://www.hhs.gov/press-room/acip-recommends-covid19-vaccination-individual-decision-making.html

4. Staying up to date with COVID-19 vaccines. CDC. Updated November 19, 2025. Accessed August 27, 2026. https://www.cdc.gov/covid/vaccines/stay-up-to-date.html